Valuation dashboard for Sagimet Biosciences Inc. (SGMT) with P/E N/A, P/B 2.17, EV/EBITDA -3.87 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $10.46, SGMT has negative trailing earnings (P/E not meaningful) and an ROE of -31.96%. Market capitalisation stands at $341M.
Balance sheet quality for SGMT: current ratio of 22.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.17 |
| EV / EBITDA | -3.87 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $1.05 |
| vs Current Price | -90.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SGMT | Sagimet Biosciences Inc. | $341M | 2.17 | -32.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $10.46 |
| Market Cap | $341M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -31.96% |
| Return on Invested Capital | -20.39% |
| Return on Assets | -17.87% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACHV · ARCT · ASMB · AVIR · FHTX · HUMA · IMRX
Explore sector: Healthcare · Biotechnology
More sections of SGMT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks